Abstract
In this study, 16 experienced oncologists each measured 12 simulated tumor masses employing their usual clinical methods. Unknown to the oncologists, two pairs of these tumors were identical in size. This permitted a total of 64 measurement comparisons of the same investigator measuring the same size mass and 1920 comparisons of different investigators measuring the same size mass. If a 50% reduction in the product of perpendicular diameters is accepted as a criterion, the objective response rate due to measuring error alone was 7.8% by the same investigator and 6.8% by different investigators. If a 25% reduction criterion is used, the respective "placebo" response rates were 19% and 25%. In the clinical setting it is recommended that the 50% reduction criterion be employed and that the investigator should anticipate an objective response rate of 5 to 10% due to human error in tumor measurement.
Keywords
MedicineClinical trialMedical physicsCancerReduction (mathematics)StatisticsNuclear medicineInternal medicineMathematics
Affiliated Institutions
Related Publications
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
The endpoint in cancer research is overall survival. Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used. Measure...
An Inventory for Measuring Depression
The difficulties inherent in obtaining consistent and adequate diagnoses for the purposes of research and therapy have been pointed out by a number of authors. Pasamanick<sup>12...
Initial Experience of a Digital Training Resource for Modified Rankin Scale Assessment in Clinical Trials
Background and Purpose— The modified Rankin Scale (mRS) is the preferred measure of disability in cerebrovascular clinical trials, but its value is restricted by interobserver v...
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials
<h3>Objective.</h3> —To evaluate the effect of angiotensin-converting enzyme (ACE) inhibitors on mortality and morbidity in patients with symptomatic congestive heart failure. <...
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
LBA9003^ Background: We report updated survival and clinical activity in initially enrolled cohorts and activity by BRAF MT status in a phase I trial of concurrent and sequenced...
Publication Info
- Year
- 1976
- Type
- article
- Volume
- 38
- Issue
- 1
- Pages
- 388-394
- Citations
- 253
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
253
OpenAlex
Cite This
Charles G. Moertel,
James A. Hanley
(1976).
The effect of measuring error on the results of therapeutic trials in advanced cancer.
Cancer
, 38
(1)
, 388-394.
https://doi.org/10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a
Identifiers
- DOI
- 10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a